Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95922

UPID:
TTLL1_HUMAN

ALTERNATIVE NAMES:
Tubulin polyglutamylase TTLL1; Tubulin polyglutamylase complex subunit 3; Tubulin--tyrosine ligase-like protein 1

ALTERNATIVE UPACC:
O95922; B2RDS7; Q9BR27; Q9NRS9; Q9UMU0

BACKGROUND:
The Tubulin--tyrosine ligase-like protein 1, a key component of the neuronal tubulin polyglutamylase complex, is essential for the polyglutamylation of tubulin. This modification is critical for the proper assembly and function of microtubules in cilia and flagella, ensuring their motility and structural integrity. Its activity is also crucial for sperm flagella development and the maintenance of pluripotency in embryogenesis through the modification of KLF4.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tubulin--tyrosine ligase-like protein 1 offers a promising avenue for developing novel treatments aimed at enhancing reproductive health and understanding developmental diseases. Its role in cilia and flagella biogenesis and function underscores its potential in therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.